Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Abacus dx now distributes the HaemoScan range of products

Products are for professional/laboratory use only.

Abacus dx are pleased to announce that we are now distributing the HaemoScan range of products in Australia and New Zealand.

HaemoScan is an innovative company in the field of biomarker analysis and has developed many assays to measure complement activity.

The kits provide a quick and simple test procedure based on measurement of complement haemolytic activity for the classical (CH50) and alternative (AP50) pathways of complement. Both citrate plasma or serum can be used.

Designed for small sample volumes (50µl or less), they are simple to measure using a 96 well microtiter plate and a spectrophotometer.

HaemoScan offer the following research products:

  • AP50 Assay
  • CH50 Assay
  • Complement Convertase Assay
  • Haemolysis Assay
  • High Intensity Chemiluminescence ELISA Substrate
  • N-Acetyl-glucosaminidase Assay
  • Thrombin Generation Assay

Other complement products available from Abacus dx include MILLIPLEX Human Complement Panels 1 & 2.  Click here to find out more >

Find out more about HaemoScan products

View Flyer >

Request a quote

Contact Us Now >



Request a Quote

Request Quote

Recent Posts

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article

Merck FemtoQuest™

Gain your desired immunoassay sensitivity with the ultrasensitive FemtoQuest™ system Measure down to femtogram/mL levels Improved precision and robust data Perform dual-plex and single analyte…

Read full article

Healing Eyes with Precision: Research Empowered by Merck’s MILLIPLEX® Technology

Imagine using part of your blood to help heal your eyes A study by Liu et al. (2025) explores a new way to treat corneal neovascularization, a condition…

Read full article